MVM Partners

About The Fund

MVM Partners, founded in 1997 and headquartered in London, United Kingdom, is a venture capital fund that specializes in investments across the healthcare sector. With additional offices in Boston, Massachusetts, and presence in the San Francisco Bay Area, MVM focuses on equity investments in high-growth potential companies within specialty pharmaceuticals, medical technology, diagnostics, life science tools, consumer healthcare, veterinary medicine, healthcare services, and healthcare information technology. MVM Partners manages assets worth more than $700 million and invests in companies at various stages, including seed, startup, and early stages, with a targeted investment range of approximately $25 million per company. Their expertise in equity investments is leveraged to build world-class companies addressing significant unmet needs in large addressable markets. MVM looks for innovative products that can either tackle conditions lacking adequate treatment, therapies that are currently too expensive, or diseases with no accurate diagnostic capabilities. The firm's approach involves partnering with adept management teams to facilitate the company's growth, strategic acquisitions, and the introduction of novel standards in medicine. MVM's investment profile includes companies with differentiated technology shielded from competition through intellectual property, market entry barriers, statutory exclusivity, or unique branding. They take an active role post-investment to help businesses meet near and long-term objectives. Known for their extensive experience in guiding portfolio companies to successful exits through acquisitions and IPOs, MVM's approach to investments is not fixed but focuses on companies that can make aggregate investments of $20 to $100 million over the tenure of the holding. They are keen on maintaining a concentrated portfolio and invest in transforming companies that enable higher quality, cost-effective care across global markets. Their experience surpasses 100 collective years in healthcare investing and boasts 39 successful exits.